REXAVORN Trademark

Trademark Overview

On Monday, April 19, 2010, a trademark application was filed for REXAVORN with the United States Patent and Trademark Office. The USPTO has given the REXAVORN trademark a serial number of 85017027. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 16, 2013. This trademark is owned by Amgen Inc.. The REXAVORN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for use in the treatment of oncological diseases and disorders, and complications associated therewith
rexavorn

General Information

Serial Number85017027
Word MarkREXAVORN
Filing DateMonday, April 19, 2010
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 16, 2013
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 15, 2011

Trademark Statements

Goods and ServicesPharmaceutical preparations for use in the treatment of oncological diseases and disorders, and complications associated therewith

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, April 22, 2010
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAmgen Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799
Party NameAmgen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Trademark Events

Event DateEvent Description
Monday, December 16, 2013ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, December 16, 2013ABANDONMENT - NO USE STATEMENT FILED
Wednesday, April 3, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 2, 2013EXTENSION 4 GRANTED
Friday, March 29, 2013EXTENSION 4 FILED
Friday, March 29, 2013TEAS EXTENSION RECEIVED
Wednesday, October 10, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 9, 2012EXTENSION 3 GRANTED
Thursday, October 4, 2012EXTENSION 3 FILED
Thursday, October 4, 2012TEAS EXTENSION RECEIVED
Tuesday, March 27, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 26, 2012EXTENSION 2 GRANTED
Wednesday, March 21, 2012EXTENSION 2 FILED
Wednesday, March 21, 2012TEAS EXTENSION RECEIVED
Thursday, October 20, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 19, 2011EXTENSION 1 GRANTED
Monday, October 17, 2011EXTENSION 1 FILED
Wednesday, October 19, 2011CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, October 17, 2011TEAS EXTENSION RECEIVED
Tuesday, May 10, 2011NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 15, 2011OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 15, 2011PUBLISHED FOR OPPOSITION
Tuesday, February 8, 2011LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, February 7, 2011ASSIGNED TO LIE
Monday, January 10, 2011APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, January 10, 2011EXAMINER'S AMENDMENT ENTERED
Monday, January 10, 2011NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, January 10, 2011EXAMINERS AMENDMENT E-MAILED
Monday, January 10, 2011EXAMINERS AMENDMENT -WRITTEN
Wednesday, July 28, 2010NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, July 28, 2010NON-FINAL ACTION E-MAILED
Wednesday, July 28, 2010NON-FINAL ACTION WRITTEN
Tuesday, July 27, 2010ASSIGNED TO EXAMINER
Thursday, April 22, 2010NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, April 22, 2010NEW APPLICATION ENTERED IN TRAM

Related Keywords

rexavorn complications associated therewith disorders diseases preparations treatment oncological pharmaceutical